Tekla Life Sciences Investors (NYSE: HQL) — Perfil da empresa, notícias e dados financeiros
Tekla Life Sciences Investors is a specialized investment fund focused on life sciences, investing in healthcare innovations.
Tekla Life Sciences Investors
Abrdn Life Sciences Investors (NYSE:HQL) is a specialized investment fund focused on the life sciences sector. Its operations encompass investing in a dynamic portfolio that includes biotechnology, pharmaceuticals, life science tools, and medical devices companies across various stages of development. By channeling capital into both public and private firms that are pioneering innovations in healthcare, Tekla aims to generate long-term capital appreciation for its investors. The fund's projects include direct investments in promising life sciences companies as well as participations in industry-specific partnerships and joint ventures. Tekla Life Sciences Investors' primary objective is to identify and invest in companies that have the potential to create breakthrough medical treatments and technologies, thereby contributing to the advancement of global healthcare while seeking to provide robust returns to its shareholders.
Resumo
Operações
Produtos e/ou serviços de Tekla Life Sciences Investors
- Biopharmaceutical investments focusing on innovative drug development and therapeutic methods.
- Medical devices investment, targeting advancements in healthcare technology and diagnostic tools.
- Healthcare services funding, supporting companies that improve patient care and healthcare delivery.
- Biotechnology research financing, facilitating groundbreaking discoveries in genetics and molecular biology.
- Healthcare information technology projects, enhancing data management and patient information systems.
- Life science real estate ventures, providing infrastructure for research facilities and laboratories.
equipe executiva do Tekla Life Sciences Investors
- Daniel R. OmsteadPrincipal Executive Officer, President and Trustee
- Peter BrannerChief Investment Officer
Histórico de dividendos
Dividendos por ação pagos pela Tekla Life Sciences Investors, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026 | — | — | — | $2.2400 |
| FY2025 | — | — | — | $1.8200 |
| FY2024 | — | — | — | $1.6600 |
| FY2023 | — | — | — | $1.2800 |
| FY2022 | — | — | — | $1.4700 |
Principais indicadores financeiros
Resultados divulgados pela Tekla Life Sciences Investors, em USD.
- Cap. de mercado
- 538,2 mi
- Receita (TTM)
- 1,1 mi
- P/L
- 2.7
- LPA (diluído, TTM)
- 6.6
- Dividend yield
- 10.8%
- Margem de lucro
- 17857.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 86,4 mi | 85,6 mi | 85,6 mi | |
| 86,7 mi | 85,3 mi | 85,3 mi | |
| 23,5 mi | 22,4 mi | 22,4 mi | |
| -103,3 mi | -104,6 mi | -104,6 mi |